Objective: To determine the antipsychotic efficacy and extrapyramidal safety of intramuscular (IM) olanzapine and IM haloperidol during the first 24 hours of treatment of acute schizophrenia.
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A cutely agitated patients with schizophrenia experience great personal distress and may present a danger to themselves or others (1) . Such patients are frequently treated with intramuscular (IM) antipsychotic agents or benzodiazepines, or both, when rapid alleviation of agitation is necessary (2, 3) . IM typical antipsychotics may also reduce both positive symptoms and general psychopathology (4); however, they can cause extrapyramidal symptoms (EPS), which in turn reduces compliance with antipsychotic maintenance therapy and increases the risk of relapse (5, 6) . Also, IM typical antipsychotics must often be coadministered with benzodiazapines (7) , which further increases the risk of adverse events.
We recently reported that IM olanzapine 10.0 mg had efficacy comparable to IM haloperidol 7.5 mg for reducing acute agitation in patients with schizophrenia and that IM olanzapine had a more rapid onset of action (8) . Further, treatment with IM olanzapine was not associated with acute dystonia, whereas 7.1% of patients treated with IM haloperidol experienced this distressing adverse event. We now report additional data from the same study on the antipsychotic efficacy and extrapyramidal safety of IM olanzapine and IM haloperidol during the first 24 hours of treatment of acute schizophrenia.
Methods

Patient Population
We recruited men and women aged 18 years and over who had been diagnosed according to DSM-IV criteria with schizophrenia, schizophreniform disorder, or schizoaffective disorder. All patients had a minimum total score of 14 on the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC), which consists of the items "tension," "uncooperativeness," "hostility," "poor impulse control," and "excitement." All patients also had a score of 4 or higher on at least 1 item (1 to 7 scoring system for each item). Patients were clinically agitated and appropriate candidates for IM treatment, as assessed by the site investigator. We excluded pregnant or lactating women and patients with serious medical illnesses, for whom pharmacotherapy posed a substantial clinical risk or confounded diagnosis. The following treatments were prohibited: 1) injectable depot antipsychotic or injectable zuclopenthixol acetate 1 injection interval before the first IM injection, 2) psychostimulants or reserpine 1 week before the first IM injection, 3) benzodiazepines 4 hours before the first IM injection, and 4) oral or rapid-acting IM antipsychotic 2 hours before the first IM injection.
Study Design
The study was conducted between February 1999 and November 1999 by 51 investigators in 13 countries (specifically, Australia, Austria, Belgium, Canada, the Czech Republic, France, Greece, Hungary, Italy, the Republic of South Africa, Spain, the UK, and the US). Written informed consent was obtained from all patients after study procedures were fully explained to them.
The screening period (a minimum of 2 hours) included physical examinations and collection of standard histories and baseline measurements; no antipsychotics or sedatives were administered. Following screening, patients were randomly allocated by the assignment of treatment kits to double-blind treatment with IM olanzapine 10.0 mg, IM haloperidol 7.5 mg, or IM placebo (2:2:1 ratio; 1 to 3 injections over 24 hours, with the second injection more than 2 hours after the first, and the third injection more than 4 hours after the second, given on the basis of clinical need). The randomization ratio limited placebo exposure. IM haloperidol was chosen as a comparator because it is the IM antipsychotic agent most frequently used for treating acutely agitated schizophrenia patients (4, 9) .
One benzodiazepine dose (up to 20 mg diazepam equivalents) was allowed 1 hour or more after the second IM injection of the study drug, and a second dose was allowed 1 hour or more after the third injection. Anticholinergic medications were only permitted for the control of EPS adverse events occurring during the study. Other concomitant medications with primarily central nervous system activity were prohibited.
Assessments
Efficacy. The PANSS-derived Brief Psychiatric Rating Scale (BPRS) Total score was completed at baseline and at 2 hours and 24 hours after the first injection. Positive symptoms were evaluated with the BPRS Positive subscale, and general psychopathology was further evaluated with the Clinical Global Impressions (CGI) scale (specifically, the Severity of 
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Limitations · It will be important to determine whether our results generalize to the more severely ill patients treated in routine clinical practice. · It will be of interest to compare the EPS safety profile of IM olanzapine 10.0 mg with a lower dosage of IM haloperidol (for example, 5.0 mg). · We did not investigate potential synergies and interactions between IM olanzapine and other drugs (for example, benzodiazepines) used in the treatment of acute schizophrenia.
Illness [CGI-S] scale at baseline and the Improvement of Illness [CGI-I] scale at 24 hours after the first injection).
Extrapyramidal Safety. The incidences of treatmentemergent parkinsonism (that is, the proportion of patients with a Simpson-Angus Scale total score of more than 3, out of those with a total score 3 or less at baseline [10] ) and treatment-emergent akathisia (that is, the proportion of patients with a Barnes Akathisia Scale global score [item 4] of 2 or more, out of those with a score less than 2 at baseline [11] ) were evaluated for the 24-hour IM period. Mean changes on these EPS scales were also derived from baseline to the 24-hour endpoint.
Statistical Methods
We evaluated between-group comparisons of mean baselineto-endpoint changes in psychotic symptoms, parkinsonism, and akathisia during the IM period using an analysis of variance (ANOVA) model that included the terms for treatment and the country. Categorical data were evaluated with Fisher's exact test. All hypothesis tests were performed with a 2-sided significance level of 0.05.
Results
Patient Characteristics
In all, 311 patients were randomized (IM olanzapine n = 131, IM haloperidol n = 126, and IM placebo n = 54). Patient demographic and illness characteristics (Table 1) were comparable across treatment groups, as were baseline efficacy and EPS rating scale scores (Tables 2 and 3) .
Patient Disposition
In all, 285 (91.6%) patients completed the 24-hour IM period (IM olanzapine 93.1%, IM haloperidol 92.1%, and IM placebo 87.0%). Adverse events caused 5 patients to discontinue. Of these, 3 (2.4%) received IM haloperidol and showed acute dystonia, extrapyramidal syndrome, and neuroleptic malignant syndrome, respectively. The remaining 2 (1.5%) received IM olanzapine and showed anxiety and maculopapular rash, respectively. Significantly more patients given IM placebo (9.3%) discontinued because of lack of efficacy, compared with those treated with IM olanzapine (1.5%; Fisher's exact test, P = 0.023) or IM haloperidol (0%; Fisher's exact test, P = 0.002).
Mean Changes in Positive Symptoms and General
Psychopathology IM olanzapine and IM haloperidol were comparable and were both superior to IM placebo for reducing scores on the BPRS Positive and Total at 2 hours after the first injection and on all scales at 24 hours after the first injection ( Table 2) .
As previously reported, significantly more patients given IM placebo (38.9%) received benzodiazepines during the study, compared with patients receiving IM olanzapine (16.0%; Fisher's exact test, P = 0.002) or IM haloperidol (19.8%; Fisher's exact test, P = 0.009) (8) . Mean daily benzodiazepine dosages did not differ significantly among the groups (IM olanzapine mean 3.8, SD 4.2 mg; IM haloperidol mean 3.5, SD 2.8 mg; and IM placebo mean 3.1, SD 2.1 mg).
Categorical Incidences of Parkinsonism and Akathisia
Patients receiving IM olanzapine experienced significantly fewer incidences of treatment-emergent parkinsonism (4.3% with IM olanzapine vs 13.3% with IM haloperidol; Fisher's exact test, P = 0.036) but not akathisia (1.1% with IM olanzapine vs 6.5% with IM haloperidol; Fisher's exact test, P = 0.065), compared with patients receiving IM haloperidol, and no more incidences of either parkinsonism or akathisia than patients given IM placebo (parkinsonism 3.1% and akathisia 2.8%).
Mean Changes in EPS Measures
At 24 hours after the first injection, mean scores on EPS rating scales were significantly reduced during IM olanzapine treatment, compared with an increase during IM haloperidol treatment (Simpson-Angus Scale t 276 = 3.6, P < 0.001; Barnes Akathisia Scale t 276 = 3.1, P = 0.002) ( 
Concomitant Anticholinergic Use
As previously reported, significantly fewer patients treated with IM olanzapine (4.6%; Fisher's exact test, P < 0.001) or given IM placebo (3.7%; Fisher's exact test, P = 0.003) received anticholinergic medication, compared with patients receiving IM haloperidol (20.6%) (8) . Mean daily anticholinergic dosages were similar across all groups (IM olanzapine mean 2.0, SD 1.1 mg; IM haloperidol mean 2.7, SD 1.9 mg; and IM placebo mean 2.0, SD 0.0 mg).
Discussion
We recently reported that IM olanzapine 10.0 mg had efficacy comparable to IM haloperidol 7.5 mg for reducing acute agitation in patients with schizophrenia (8) . IM olanzapine had a more rapid onset of action, and no incidence of acute dystonia was reported during IM olanzapine treatment (compared with an incidence of 7.1% for IM haloperidol). These additional data from the same study show that IM olanzapine and IM haloperidol have comparable efficacy in reducing positive symptoms and general psychopathology during the first 24 hours after the first injection. IM olanzapine also demonstrated a more favourable EPS safety profile than did IM haloperidol, with no reports of acute dystonia and significantly fewer reports of treatment-emergent parkinsonism.
Efficacy in reducing positive symptoms and general psychopathology are important during the treatment of patients with a 24-hour overall treatment effect from the main effects model with terms for treatment and country using raw data: Simpson-Angus Scale F2,276 = 9.6, P < 0.001; Barnes Akathisia Scale F2,276 = 4.8, P = 0.009. b P < 0.001 vs intramuscular haloperidol. c P < 0.05 vs intramuscular haloperidol.
acute schizophrenia, not only to reduce subjective distress but also because these symptoms have been correlated with violence (12, 13) . In this study, IM olanzapine was comparable to IM haloperidol for reducing positive symptom and general psychopathology scores as early as 2 hours after an injection (with the first measurement taken at 2 hours) and for at least 24 hours. Oral olanzapine has demonstrated superiority over oral haloperidol in improving overall psychopathology (14) .
Parkinsonism and akathisia can be extremely distressing, and patients can be understandably reluctant to continue antipsychotic maintenance therapy after experiencing these adverse events (5) . Medication noncompliance in general is the leading cause of relapse in schizophrenia (6) . The overall favourable EPS safety profile of IM olanzapine could potentially enhance patients' adherence to antipsychotic maintenance therapy, but this requires further research. The findings of significantly less acute dystonia and treatment-emergent parkinsonism and significantly improved scores on EPS rating scales during IM olanzapine treatment, compared with IM haloperidol treatment, are consistent with oral olanzapine clinical trial literature (14) (15) (16) .
This study has some important limitations. First, the applicability of our results to more severely ill patients treated in routine clinical practice needs to be determined, since ethical considerations prevent their recruitment to clinical trials. Nonetheless, we took care to include patients who were ill enough for any effect of active treatment on their symptoms to be evident but not so ill that they were unable to provide informed consent or cooperate with the clinical trial requirements. The suitability of the enrolled patients is attested to by their response to IM haloperidol, which is known to effectively reduce symptoms of schizophrenia. Second, future studies are needed to investigate a range of IM medication dosages (for example, a lower dosage of IM haloperidol). Third, we did not investigate potential synergies and interactions between IM olanzapine and other drugs used for treating acute schizophrenia (for example, benzodiazepines). Finally, further research is required to test the hypothesis that the efficacy and EPS safety advantages of IM olanzapine can reduce subjective distress and the risk of violence in patients with schizophrenia, leading to enhanced compliance with antipsychotic maintenance therapy and prevention of relapse.
In summary, IM olanzapine and IM haloperidol were comparable in reducing the symptoms of acute schizophrenia during the first 24 hours of treatment, their efficacy being evident within 2 hours after the first injection. Generally more EPS were observed during treatment with IM haloperidol than with IM olanzapine. Overall, the data from this clinical trial suggest that IM olanzapine is an efficacious, yet safer, alternative to IM haloperidol for the treatment of both acute agitation and psychotic symptomatology in patients with schizophrenia. Further, because it has been suggested that early clinical improvement predicts a more favourable eventual outcome (17) , the rapid alleviation of agitation and early reduction of positive symptoms during treatment with IM olanzapine could improve the prognosis of some patients with schizophrenia. Conclusion : L'olanzapine IM était comparable à l'halopéridol IM pour réduire les symptômes de la schizophrénie aiguë durant les 24 premières heures du traitement, l'efficacité des deux médicaments étant évidente moins de deux heures après la première injection. En général, plus de SEP ont été observés durant le traitement à l'halopéridol IM qu'à l'olanzapine IM.
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